COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,363 Articles (22,803 medRxiv, 8,560 bioRxiv)

Most recent first Previous |  Page 920: Articles 9191-9200  | Next

Dynamics of the Delta and Omicron variants of SARS-CoV-2 in the United States: the battle of supremacy in the presence of vaccination, mask usage and antiviral treatment
Ngonghala, C. N., Taboe, H. B., Gumel, A. B.
10.1101/2022.02.23.22271394 — Posted: 2022-02-24
Fourth Wave of COVID-19 in India : Statistical Forecasting
Rajeshbhai, S. P., Dhar, S. S., Shalabh, S.
10.1101/2022.02.23.22271382 — Posted: 2022-02-24
Bounce backs amid continued losses: Life expectancy changes since COVID-19
Schoeley, J., Aburto, J. M., Kashnitsky, I., Kniffka, M. S., Zhang, L., Jaadla, H., Dowd, J. B., Kashyap, R.
10.1101/2022.02.23.22271380 — Posted: 2022-02-24
Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study
Ayoubkhani, D., Bosworth, M. L., King, S., Pouwels, K. B., Glickman, M., Nafilyan, V., Zaccardi, F., Khunti, K., Alwan, N. A., Walker, A. S.
10.1101/2022.02.23.22271388 — Posted: 2022-02-24 Discussion: Onsite
Increase in SARS-CoV-2 RBD-specific IgA and IgG Antibodies in Breast Milk from Lactating Women Following the COVID-19 Booster Vaccination
Henle, A. M.
10.1101/2022.02.23.22271414 — Posted: 2022-02-24
Third dose of COVID-19 vaccine, CVnCoV, increased neutralizing activity against SARS-CoV-2 wild-type and Delta variant
Wolz, O.-O., Kays, S.-K., Junker, H., Koch, S. D., Mann, P., Quintini, G., von Eisenhart-Rothe, P., Oostvogels, L.
10.1101/2022.02.22.22271051 — Posted: 2022-02-24
Bacterial metatranscriptomes in wastewater can differentiate virally infected human populations
Salido, R. A., Martino, C., Karthikeyan, S., Huang, S., Rahman, G., Gonzalez, A., Zaramela, L. S., Beck, K. L., Bhute, S., Cantrell, K., Carrieri, A. P., Farmer, S., Haiminen, N., Humphrey, G., Kim, H.-C., Parida, L., Richter, R. A., Vazquez-Baeza, Y., Zengler, K., Swafford, A., Bartko, A., Knight, R.
10.1101/2022.02.23.481658 — Posted: 2022-02-24
Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., van Royen, M. E., Molenkamp, R., Oude Munnink, B., de Vries, R. D., GeurtsvanKessel, C., Smith, D. J., Koopmans, M., Rockx, B., Lamers, M. M., Fouchier, R., Haagmans, B.
10.1101/2022.02.23.481644 — Posted: 2022-02-24
Pre-clinical testing of two serologically distinct chimpanzee-origin adenovirus vectors expressing spike of SARS-CoV-2
Novikov, M., Hasanpourghadi, M., Ambrose, R., Chekaoui, A., Newman, D., Giles-Davis, W., Zhou, X., Xiang, Z., Ertl, H. C. J.
10.1101/2022.02.23.481620 — Posted: 2022-02-24
A high-throughput yeast display approach to profile pathogen proteomes for MHC-II binding
Huisman, B. D., Dai, Z., Gifford, D. K., Birnbaum, M. E.
10.1101/2022.02.22.480950 — Posted: 2022-02-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).